SC
CRSP icon

SouthState Corp’s CRISPR Therapeutics CRSP Stock Holding History

SouthState Corp’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.73K Hold
50
– – ﹤0.01% 894
2026
Q1 		$2.38K Hold
50
– – ﹤0.01% 869
2025
Q4 		$2.62K Buy
+50
New +$2.99K ﹤0.01% 932
2025
Q2 		– Sell
-125
Closed -$4.25K – 1643
2025
Q1 		$4.25K Hold
125
– – ﹤0.01% 1023
2024
Q4 		$4.92K Hold
125
– – ﹤0.01% 576
2024
Q3 		$5.87K Hold
125
– – ﹤0.01% 510
2024
Q2 		$6.75K Buy
+125
New +$7.23K ﹤0.01% 518

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SouthState Corp's CRSP Position: Q2 2026 in Review

SouthState Corp held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 50 shares worth $2.73K. The position accounts for ﹤0.01% of the portfolio, ranked #894.

SouthState Corp first reported a position in CRSP in Q2 2024 and has held it in 7 quarters since. The position peaked at $6.75K in Q2 2024. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • SouthState Corp held 50 shares of CRISPR Therapeutics worth $2.73K as of Q2 2026.
  • SouthState Corp left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of SouthState Corp's portfolio in Q2 2026, its #894 holding.
  • SouthState Corp first reported a position in CRISPR Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • SouthState Corp's CRISPR Therapeutics position peaked at $6.75K in Q2 2024.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on SouthState Corp's 13F filing for Q2 2026, filed 6 Aug 2026.